Portfolio company Silence acquired by Merck KGaA
Summary by AI BETAClose X
INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")
IBT portfolio company Silence to be acquired by Merck KGaA
IBT notes the announcement today that Silence Therapeutics (Silence) has entered into a definitive agreement to be acquired by Merck KGaA (Merck).
Silence is a UK-based global clinical-stage biotechnology company developing precision engineered medicines using its proprietary SiRNA (short interfering RNA) technology. Divesiran, the company's most advanced program, has the FDA's Fast Track and Orphan Drug designations for the treatment of polycythemia vera (PV), a rare form of blood cancer.
Under the terms of the agreement, Silence shareholders will receive $20 per share in cash at closing, representing a premium of approximately 130% to Silence's closing share price on 16 October. As at close of business on 16 October, Silence represented 0.7% of IBT's Net Asset Value, as included in IBT's daily NAV update on 19 October.
Commenting on the news, Ailsa Craig and Marek Poszepczynski, portfolio managers of IBT, said:
"The pharmaceutical sector's shopping spree for biotech companies continues, with pharma firms willing to pay significant premiums for innovative biotech businesses in the face of a historic wave of patent expiries in the coming years.
We have now seen nine portfolio companies acquired so far in 2026, matching the total for 2025 and showing the effectiveness of our stock selection process, which evaluates biotech companies through the same lens as potential acquirers. The structural drivers of M&A remain firmly in place, as the acquisitions we have seen this year only scratch the surface of the pharmaceutical sector's patent cliff."
The updated valuation of IBT's holding in Silence will be included in IBT's NAV as at close of business on 19 October, to be reported in the usual way on 20 October.
To sign up for IBT updates by email, please click here.
ENDS
Enquiries:
|
Schroder Investment Management Limited Kirsty Preston (PR) Michelle Taiwo/Natalia de Sousa (Company Secretary)
|
020 7658 6000 020 7658 6000
|
|
Kaso Legg Communications (Financial PR) Charles Gorman Henry Taylor Effie Aye Maung Hider |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund